Tocagen SNO 2017 Investor & Analyst Breakfast

November 19, 2017

Please contact Clayton Robertson (crobertson@troutgroup.com) for additional details and to RSVP. 

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Tocagen Inc. [TOCA] US$175 MM MCap
Can­cer-se­lec­tive gene ther­a­py com­pany. Lead pro­gram To­ca 511 and To­ca FC are be­ing studied in a reg­is­tra­tio­n­al Ph 2/3 trial for re­cur­rent high grade glio­ma (rHGG). A Ph 1 study of To­ca 511 and To­ca FC... [more in­for­ma­tion]

Event Contact

Clayton Robertson
Solebury Trout